在前列腺癌中保护雄激素受体和其他新兴疗法
Peter D Zang1, Allen Seylani2, Evan Y Yu3,4
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
像PROTACs,DAARIs和anitens这样的新疗法显示出通过向雄激素受体 (AR) 来克服晚期前列腺癌中抵抗力的承诺. 对抗性机制的进一步研究将优化AR信号抑制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 雄激素受体 (AR) 驱动前列腺癌的进展.
- 雄激素受体通路抑制剂 (ARPIs) 已经得到了先进的治疗,但耐药性正在出现.
- 抵抗机制包括AR突变,过度表达和替代信号.
研究的目的:
- 审查新兴的AR向治疗方法.
- 评估可能绕过ARPI耐药性的药物.
- 讨论前列腺癌晚期治疗的新方法.
主要方法:
- 在PubMed (2000-2024) 的文献搜索.
- 对蛋白质分解向喜梅拉 (PROTAC) 剂的审查.
- 对双作用雄激素受体抑制剂 (DAARI) 和anitens的分析.
主要成果:
- PROTACs,DAARIs和anitens是有前途的AR准剂,它们可以在AR中进行定位.
- 这些新型疗法可能会克服抵抗机制.
- 这些药物的早期临床数据正在出现.
结论:
- 在前列腺癌治疗中,PROTAC,DAARI和anitens代表了一个新的前沿.
- 了解耐药性是最大化疗效的关键.
- 这些药物有可能成为未来的前列腺癌治疗策略.
更多相关视频
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
